TP53/EGFR基因共突变对肺腺癌患者EGFR-TKIs疗效的影响
|
摘要
目的探讨TP53/EGFR基因共突变对肺腺癌(LUAD)患者表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)疗效的影响。方法回顾性分析TP53/EGFR基因共突变晚期LUAD患者临床病理资料,分析其临床特征与TP53/EGFR基因突变的关系,并进行生存分析。采用多因素Cox回归模型分析TP53/EGFR基因共突变与EGFR-TKIs疗效及预后关系。结果 100例LUAD患者中,TP53/EGFR基因共突变44例,突变率44.0%(44/100)。一线接受EGFR-TKIs治疗单纯表皮生长因子受体(EGFR)基因突变LUAD患者的无进展生存时间(PFS)较TP53/EGFR基因共突变LUAD患者显著延长(P<0.05)。单纯EGFR基因突变LUAD患者的EGFR-TKIs客观缓解率(ORR)和疾病控制率(DCR)高于TP53/EGFR基因共突变LUAD患者。结论 TP53基因突变与EGFR基因突变的LUAD患者使用EGFR-TKIs的疗效有一定相关性。
Objective To analyze the effect of TP53/EGFR gene co-mutation on the treatment of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(EGFR-TKIs) in patients with lung adenocarcinoma.Methods The clinical and pathological data of patients with advanced lung adenocarcinoma of EGFR mutation were retrospectively analyzed. The relationship between clinical features and TP53/EGFR gene mutations was analyzed and survival analysis was performed. Multivariate Cox regression model was used to analyze the relationship between TP53 gene mutation and EGFR-TKIs efficacy and prognosis.Results In the 100 patients with lung adenocarcinoma, 44 were TP53/EGFR co-mutated, with a mutation rate of 44.0%(44/100). The progression-free survival time(PFS) of patients with lung adenocarcinoma with EGFR-TKIs treated with EGFR-TKIs was significantly longer than that of patients with lung adenocarcinoma with TP53/EGFR gene mutation(P<0.05). EGFR-TKIs with simple EGFR gene mutation in patients with lung adenocarcinoma displayed higher objective rate(ORR) and disease control rate(DCR) than patients with TP53/EGFR gene co-mutation lung adenocarcinoma.Conclusion There is a correlation between the TP53 gene mutation and the EGFR gene mutation in lung adenocarcinoma patients using EGFR-TKIs.
Objective To analyze the effect of TP53/EGFR gene co-mutation on the treatment of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(EGFR-TKIs) in patients with lung adenocarcinoma.Methods The clinical and pathological data of patients with advanced lung adenocarcinoma of EGFR mutation were retrospectively analyzed. The relationship between clinical features and TP53/EGFR gene mutations was analyzed and survival analysis was performed. Multivariate Cox regression model was used to analyze the relationship between TP53 gene mutation and EGFR-TKIs efficacy and prognosis.Results In the 100 patients with lung adenocarcinoma, 44 were TP53/EGFR co-mutated, with a mutation rate of 44.0%(44/100). The progression-free survival time(PFS) of patients with lung adenocarcinoma with EGFR-TKIs treated with EGFR-TKIs was significantly longer than that of patients with lung adenocarcinoma with TP53/EGFR gene mutation(P<0.05). EGFR-TKIs with simple EGFR gene mutation in patients with lung adenocarcinoma displayed higher objective rate(ORR) and disease control rate(DCR) than patients with TP53/EGFR gene co-mutation lung adenocarcinoma.Conclusion There is a correlation between the TP53 gene mutation and the EGFR gene mutation in lung adenocarcinoma patients using EGFR-TKIs.
引文
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] Huang Q,Li J,Sun Y,et al.Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis[J].Chest,2016,149(6):1384-92.
[3] Canale M,Petracci E,Delmonte A,et al.Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors[J].Clin Cancer Res,2017,23(9):2195-202.
[4] Ettinge D S,Wood D E,Akerley W,et al.Nccn guidelines insights:non-small cell lung cancer,version 4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-64.
[5] Gao W,Jin J,Yin J,et al.KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients[J].Mol Carcinog,2017,56(2):381-8.
[6] 卞春安,李忠佑,许有涛,等.突变型P53蛋白在肺腺癌中的表达及其临床意义[J].中国肺癌杂志,2015,18(1):23-8.
[7] Halvorsen A R,Silwal-Pandit L,Meza-Zepeda L A,et al.TP53 mutation spectrum in smokers and never smoking lung cancer patients[J].Front Genet,2016,7:85.
[8] Molina-Vila M A,Bertran-Alamillo J,Gasco A,et al.Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer[J].Clin Cancer Res,2014,20(17):4647-59.
[9] Ferrell B R,Temel J S,Temin S,et al.Integration of palliative care into standard oncology care:ASCO clinical practice guideline update summary[J].J Oncol Pract,2017,13(2):119-21.
[10] Jiao X D ,Qin B D,You P,et al.The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer,an analysis based on cbioportal data base[J].Lung Cancer,2018,123:70-5.
[11] VanderLaan P A,Rangachari D,Mockus S M,et al.Mutations in TP53,PIK3CA,PTEN and other genes in EGFR mutated lung cancers:Correlation with clinical outcomes[J].Lung cancer,2017,106:17-21.
[12] Bria E,Pilotto S,Amato E,et al.Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung ad-enocarcinoma[J].Oncotarget,2015,6(14):12783-95.
[13] Labbé C,Cabanero M,Korpanty G J,et al.Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer(NSCLC)[J].Lung Cancer,2017,111:23-9.
[2] Huang Q,Li J,Sun Y,et al.Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis[J].Chest,2016,149(6):1384-92.
[3] Canale M,Petracci E,Delmonte A,et al.Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors[J].Clin Cancer Res,2017,23(9):2195-202.
[4] Ettinge D S,Wood D E,Akerley W,et al.Nccn guidelines insights:non-small cell lung cancer,version 4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-64.
[5] Gao W,Jin J,Yin J,et al.KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients[J].Mol Carcinog,2017,56(2):381-8.
[6] 卞春安,李忠佑,许有涛,等.突变型P53蛋白在肺腺癌中的表达及其临床意义[J].中国肺癌杂志,2015,18(1):23-8.
[7] Halvorsen A R,Silwal-Pandit L,Meza-Zepeda L A,et al.TP53 mutation spectrum in smokers and never smoking lung cancer patients[J].Front Genet,2016,7:85.
[8] Molina-Vila M A,Bertran-Alamillo J,Gasco A,et al.Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer[J].Clin Cancer Res,2014,20(17):4647-59.
[9] Ferrell B R,Temel J S,Temin S,et al.Integration of palliative care into standard oncology care:ASCO clinical practice guideline update summary[J].J Oncol Pract,2017,13(2):119-21.
[10] Jiao X D ,Qin B D,You P,et al.The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer,an analysis based on cbioportal data base[J].Lung Cancer,2018,123:70-5.
[11] VanderLaan P A,Rangachari D,Mockus S M,et al.Mutations in TP53,PIK3CA,PTEN and other genes in EGFR mutated lung cancers:Correlation with clinical outcomes[J].Lung cancer,2017,106:17-21.
[12] Bria E,Pilotto S,Amato E,et al.Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung ad-enocarcinoma[J].Oncotarget,2015,6(14):12783-95.
[13] Labbé C,Cabanero M,Korpanty G J,et al.Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer(NSCLC)[J].Lung Cancer,2017,111:23-9.